OnKure Therapeutics
OKUR
58 hedge funds and large institutions have $208M invested in OnKure Therapeutics in 2023 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 22 increasing their positions, 13 reducing their positions, and 4 closing their positions.
150% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 4
69% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 13
23% more capital invested
Capital invested by funds: $169M → $208M (+$39.4M)
12% more funds holding
Funds holding: 52 → 58 (+6)
3% more ownership
Funds ownership: 77.94% → 80.94% (+3%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
60% less call options, than puts
Call options by funds: $8K | Put options by funds: $20K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$3.06M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$2.23M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$1.38M |
| 4 |
BlackRock
New York
|
+$1.1M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$1.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
ExodusPoint Capital Management
New York
|
-$1.2M |
| 2 |
JGC
J. Goldman & Co
New York
|
-$1.02M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.02M |
| 4 |
OCA
Octagon Capital Advisors
New York
|
-$603K |
| 5 |
Walleye Capital
New York
|
-$325K |
OKUR Hedge Fund Activity: Q3 2023 in Review
58 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in OnKure Therapeutics (OKUR) for Q3 2023, worth a combined $208M — up 23% from $169M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new OKUR positions and 4 closed out — a net gain of 6 holders — while 22 added to existing stakes and 13 trimmed.
The largest buyer was Invesco, opening a new position worth an estimated $3.06M. The largest seller was ExodusPoint Capital Management, cutting an estimated $1.2M.
- 58 institutional investors held OnKure Therapeutics (OKUR) as of Q3 2023, up from 52 in Q2 2023.
- Funds reported $208M of OnKure Therapeutics stock for Q3 2023, up 23% quarter-over-quarter.
- 10 funds opened new OnKure Therapeutics positions in Q3 2023 and 4 closed out, a net change of +6 holders.
- The largest OnKure Therapeutics buyer in Q3 2023 was Invesco, an estimated $3.06M added.
- The largest OnKure Therapeutics seller in Q3 2023 was ExodusPoint Capital Management, an estimated $1.2M sold.
Based on aggregated 13F filings for Q3 2023.